We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 1,043% below its sector, cheaper than its peers on earnings.
Welgene Biotech Co.,Ltd. primarily focuses on delivering genetic analysis services. The company provides comprehensive support for scientific research, employing a range of advanced laboratory techniques such as genetic sequencing, microarray analysis, qPCR verification, nucleic acid extraction and quality control, LCM single cell experimentation, and intricate bioinformatics analysis. A key offering in their portfolio is Cytoscan, an array-based comparative genomic hybridization (CGH) solution. Beyond services, Welgene Biotech also supplies essential laboratory products, including various reagents, consumable items, and specialized instruments, alongside dedicated software solutions. Established in 2003, the company operates from its headquarters in Taipei City, Taiwan.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 6661.TWO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
